close 73% inwestorów detalicznych traci pieniądze podczas handlu CFD z tym dostawcą. Inwestowanie wiąże się z ryzykiem i nie jest odpowiednie dla wszystkich inwestorów. Kontrakty CFD są złożonymi instrumentami i wiążą się z dużym ryzykiem szybkiej utraty środków pieniężnych z powodu dźwigni finansowej. 73% rachunków inwestorów detalicznych notuje stratę pieniędzy podczas handlu kontraktami CFD z tym dostawcą. Upewnij się, czy rozumiesz, jak działają kontrakty CFD, i czy możesz pozwolić sobie na wysokie ryzyko utraty pieniędzy.
Change languagePolski
Pulpit

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

Strona główna・Stock List・Nektar Therapeutics
Search

Nektar Therapeutics

Closed

38.08 2.34

Buy

Price update 2 lut 2026, 20:59 UTC

BuySell

Overview

Share price change

24h

Current

Min

37.05

Max

39.36

Key metrics

By Trading Economics

Income

6.1M

-36M

Sales

615K

12M

EPS

-1.87

Profit margin

-301.289

Employees

61

EBITDA

6.9M

-29M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+178.27% upside

Dividends

By Dow Jones

Next Earnings

11 mar 2026

Market Stats

By TradingEconomics

Market Cap

-383M

756M

Previous open

35.74

Previous close

38.08

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

0.5949 / 0.7406 Support & Resistance

Nektar Therapeutics Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

2 lut 2026, 23:52 UTC

Acquisitions, Mergers, Takeovers

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

DJ

Read

2 lut 2026, 23:52 UTC

Acquisitions, Mergers, Takeovers

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

DJ

Read

2 lut 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

DJ

Read

2 lut 2026, 23:38 UTC

Market Talk

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

DJ

Read

2 lut 2026, 23:28 UTC

Market Talk

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

DJ

Read

2 lut 2026, 23:23 UTC

Earnings

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

DJ

Read

2 lut 2026, 22:57 UTC

Earnings

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

DJ

Read

2 lut 2026, 22:22 UTC

Acquisitions, Mergers, Takeovers

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

DJ

Read

2 lut 2026, 22:08 UTC

Market Talk

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

DJ

Read

2 lut 2026, 21:51 UTC

Earnings

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

DJ

Read

2 lut 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

DJ

Read

2 lut 2026, 21:49 UTC

Earnings

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

DJ

Read

2 lut 2026, 21:39 UTC

Earnings

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

DJ

Read

2 lut 2026, 21:36 UTC

Earnings

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

DJ

Read

2 lut 2026, 21:34 UTC

Earnings

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

DJ

Read

2 lut 2026, 21:28 UTC

Acquisitions, Mergers, Takeovers

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

DJ

Read

2 lut 2026, 21:23 UTC

Earnings

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

DJ

Read

2 lut 2026, 21:19 UTC

Earnings

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

DJ

Read

2 lut 2026, 21:17 UTC

Earnings

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

DJ

Read

2 lut 2026, 21:17 UTC

Earnings

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

DJ

Read

2 lut 2026, 21:10 UTC

Earnings

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

DJ

Read

2 lut 2026, 21:08 UTC

Earnings

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

DJ

Read

2 lut 2026, 21:07 UTC

Earnings

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

DJ

Read

2 lut 2026, 21:05 UTC

Earnings

Palantir Technologies 4Q Net $608.7M >PLTR

DJ

Read

2 lut 2026, 21:05 UTC

Earnings

Palantir Technologies 4Q Rev $1.41B >PLTR

DJ

Read

2 lut 2026, 21:05 UTC

Earnings

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

DJ

Read

2 lut 2026, 21:05 UTC

Earnings

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

DJ

Read

2 lut 2026, 21:05 UTC

Earnings

Palantir Technologies 4Q Adj EPS 25c >PLTR

DJ

Read

2 lut 2026, 21:05 UTC

Earnings

Palantir Technologies 4Q EPS 24c >PLTR

DJ

Read

2 lut 2026, 20:40 UTC

Market Talk

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

DJ

Read

Peer Comparison

Price change

Nektar Therapeutics Forecast

Price Target

By TipRanks

178.27% upside

12 Months Forecast

Average 103.88 USD  178.27%

High 135 USD

Low 30 USD

Based on 9 Wall Street analysts offering 12 month price targets forNektar Therapeutics - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

9 ratings

7

Buy

1

Hold

1

Sell

Based on 9 analysts giving stock ratings to Nektar Therapeutics - Dist in the past 3 months.

Technical Score

By Trading Central

0.5949 / 0.7406Support & Resistance

Short Term

Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Intermediate Term

Strong Bearish Evidence

All events are bearish.

Long Term

Bearish Evidence

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

Other stocks from the sector

JNJ

Johnson and Johnson

230.64

↑ +1.43%

ISRG

Intuitive Surgical Inc

496

↓-1.52%

ABT

Abbott Laboratories

109.39

↑ +0.15%

RDY

Dr Reddy's Laboratories Ltd-ADR

13.59

↑ +1.42%

NEOG

Neogen Corp

10.23

↑ +0.2%
help-icon Live chat